Olopatadine

CHEMBL1189432 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

337.4 g/mol

LogP

1.5

Phase

4

An antihistamine and mast cell stabilizer treating eye allergies, nasal allergies, and atopic dermatitis.

Peso molecular

337,4000 g/mol

LogP

1,50

TPSA

49,80 Å²

Regla de cinco de Lipinski

Cumple

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21

InChI

InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-

Molecular Formula

C21H23NO3

HBD / HBA

1 / 4

Enlaces Rotables

5

Átomos Pesados

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

An antihistamine and mast cell stabilizer treating eye allergies, nasal allergies, and atopic dermatitis.

Yes, Olopatadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1189432. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5281071. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Olopatadine en PillFYI

Estructura

Datos Rápidos

Fórmula: C21H23NO3
Sinónimos: 23

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.